Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
3(75%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
4
100%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
N/ANon-phased studies
4(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Completed(1)

Detailed Status

Recruiting3
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
3
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A4 (100.0%)

Trials by Status

recruiting375%
completed125%

Recent Activity

3 active trials
Showing 4 of 4
recruitingnot_applicable

Alpha Radiation Emitters Device (DaRT) for the Treatment of Liver Metastases

NCT05829291
recruitingnot_applicable

A Safety and Efficacy Study for Combinational Treatment of DaRT and Check Point Inhibitor for Recurrent Unresectable or mHNSCC

NCT05047094
recruitingnot_applicable

A Study of Diffusing Alpha Radiation Therapy for Patients With Breast Carcinoma in Frail or Elderly Patients.

NCT06202118
completednot_applicable

Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma

NCT03015883

Clinical Trials (4)

Showing 4 of 4 trials
NCT05829291Not Applicable

Alpha Radiation Emitters Device (DaRT) for the Treatment of Liver Metastases

Recruiting
NCT05047094Not Applicable

A Safety and Efficacy Study for Combinational Treatment of DaRT and Check Point Inhibitor for Recurrent Unresectable or mHNSCC

Recruiting
NCT06202118Not Applicable

A Study of Diffusing Alpha Radiation Therapy for Patients With Breast Carcinoma in Frail or Elderly Patients.

Recruiting
NCT03015883Not Applicable

Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma

Completed

All 4 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
4